Xarelto Bleeding Events Subject of New Study

A study funded by Bayer Healthcare and Janssen Pharmaceuticals—manufacturers of the blood-thinner Xarelto—was published in the medical journal Clinical Cardiology on January 14, 2015 uncovering some startling news about the new-generation anticoagulant and its side effects that can cause fatal bleeds. Researchers from Baylor College of Medicine found that serious side effects of Xarelto were consistent with Xarelto’s clinical trials, pre-FDA approval. In this study, 14 patients passed away due to unstoppable bleeding from the drug, and 478 patients experienced 496 major bleeding events—meaning that some people experienced more than one bleeding event. This study highlights the dangers Xarelto can pose, given the lack of an available bleeding antidote, though it remains a popular, highly-marketed drug.

Real Time Analytics